Delcath Systems (NSDQ:DCTH) has raised $2 million after selling 2,360 shares of Series B preferred stock at $1,000 per share to unnamed institutional investors, according to a regulatory filing. The company wrote that it plans to use the proceeds for general corporate purposes. Delcath is developing a system for liver-directed high dose chemotherapy, which involves a […]
Vascular
SteadyMed seeks FDA nod for Trevyent drug-device combo
SteadyMed (NSDQ:STDY) said today that it submitted a new drug application to the FDA for its drug-device pulmonary arterial hypertension therapy. The San Ramon, Calif.-based company’s lead product candidate is a combination of treprostinil and the PatchPump prefilled, disposable infusion system. “The submission of our NDA for Trevyent is the latest in a series of significant […]
TriReme Medical touts Chocolate Heart drug-coated balloon data
QT Vascular subsidiary TriReme Medical touted angiographic data today from a 24-month follow-up of patients treated with its Chocolate Heart drug-coated balloon. The Chocolate Heart device is a paclitaxel-coated version of the company’s Chocolate coronary balloon that is commercially available in the U.S. The combo therapy was designed to reduce the incidence of repeat procedures […]
Study: Induced pluripotent stem cells could yield accurate models for vascular disease
Smooth muscle and vascular endothelial cells induced from pluripotent stem cells could help model rare vascular diseases, according to a study published in Stem Cells Translational Medicine. Vascular diseases are tricky to study because they are hard to model and human tissue samples are scarce. An appropriate model for real blood vessels could enable researchers to […]
Study: Ekos ultrasound device provides relief to patients with chronic deep vein thrombosis
BTG (LON:BTG) touted data last week showing that patients with chronic deep vein thrombosis and post-thrombotic syndrome can be safely and effectively treated with the Ekos device and anti-coagulation drugs. The study’s protocol is the 1st treatment regimen proven to reduce the symptoms of PTS and demonstrate an improvement in quality of life for patients […]
BTG touts digital patient engagement platform with TheraSphere treatment
BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy. The study found that patients experienced sustained quality of life up to 3 months after treatment. The company touted the study of […]
Amaranth Medical looks to recapture the potential of bioresorbable scaffolds
Dr. Antonio Colombo had finished his presentation of 9-month data for Amaranth Medical‘s Aptitude sirolimus-eluting bioresorbable scaffold when an audience member asked about adverse events. He told the EuroPCR attendee that they hadn’t seen any adverse events related to the device during the trial – and that’s unusual. Bioresorbable scaffolds, like Abbott‘s (NYSE:ABT) Absorb, have been […]
Ultrasound-drug combo treats pulmonary embolism in less time with fewer drugs
When venous clots break off and travel through a patient’s circulatory system, they can become trapped in the lung and block blood flow. This strains the heart’s ability to pump blood through the lungs and can ultimately lead to heart failure. Traditionally, patients with pulmonary embolisms are treated overnight with systemic infusions of tissue plasminogen […]
Medtronic launches study of In.Pact Admiral drug-coated balloon in end-stage renal disease
Medtronic (NYSE:MDT) said today that the 1st patient was enrolled in a study of its In.Pact Admiral drug-coated balloon in patients with end-stage renal disease. The FDA approved the investigational device exemption study to evaluate the device as a treatment for failing arteriovenous fistulas in end-stage renal disease patients. “We are delighted to enroll and treat […]
Symic Bio raises $30m for peripheral vein graft failure therapy
Symic Bio said yesterday that it raised $30 million in a Series B financing round, led by existing investors and HEDA Ventures. Funds from the round are slated to support the company’s clinical programs, including a drug designed to prevent peripheral vein graft failure, SB-030, and a therapy for pain management of osteoarthritis of the knee, […]